Reports & eBooks

Drug Pipeline & Clinical Update - June 2025

June 30, 2025

Capital Rx

Highlights

  • Five key new drug approvals, including IbtroziTM (taletrectinib) for treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in adults
  • Four notable expanded indications including Mavyret® (glecaprevir/pibrentasvir) – expanded to treat acute or chronic hepatitis C virus (HCV) infection in patients at least 3 years of age, with or without compensated cirrhosis (Child-Pugh A)
  • Two generic launches including Tasigna® (nilotinib)
  • Capital Rx's Updated Drug Recall Report: CLICK HERE to review

Capital Rx's Clinical Team closely monitors the drug landscape to provide our clients with timely information on newly FDA-approved medications, as well as products in the pipeline. Read on to review our June 2025 Monthly Drug Update!

Key New Drug Approvals

Tryptyr® (acoltremon) ophthalmic solution

Approval Date: 5/28/2025

Indication: Treatment of the signs and symptoms of dry eye disease (DED)

Cost*: TBD

Key Consideration:
• First-in-class TRPM8 receptor agonist that rapidly stimulates natural tear production
• Recommended dose is 1 drop in each eye twice daily (approximately 12 hours apart)
• Available in single dose vials

Press Release: https://investor.alcon.com/news-and-events/press-releases/news-details/2025/Alcon-Announces-FDA-Approval-of-TRYPTYR-acoltremon-ophthalmic-solution-0-003-for-the-Treatment-of-the-Signs-and-Symptoms-of-Dry-Eye-Disease/default.aspx

Khindivi™ (hydrocortisone) solution

Approval Date: 5/28/2025

Indication: Corticosteroid replacement therapy in patients 5 years of age and older with adrenocortical insufficiency

Cost*: TBD

Key Consideration:
• First and only FDA approved hydrocortisone oral solution
• Ready to use oral liquid solution that does not require refrigeration, mixing, or shaking
• Dosing is based on Body Surface Area (BSA)

Press Release: https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-announces-us-fda-approval-khindivitm

Widaplik™ (telmisartan; amlodipine; indapamide) tablet

Approval Date: 6/5/2025

Indication: Treatment of hypertension

Cost*: TBD

Key Consideration:
• First and only triple combination of an angiotensin II receptor blocker (telmisartan), calcium channel blocker (amlodipine), and thiazide-like diuretic (indapamide)
• First and only triple combination approved for the initial treatment of hypertension
• Black Box Warning for use in pregnancy

Press Release: https://george-medicines.com/george-medicines-announces-fda-approval-of-widaplik-telmisartan-amlodipine-and-indapamide-a-new-single-pill-combination-treatment-for-hypertension-in-adults-including-initial-treatment/

Ibtrozi™ (taletrectinib) capsule

Approval Date: 06/11/2025

Indication: Treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in adults

Cost*: TBD

Key Consideration:
• Received Priority Review and Orphan Drug Designation by the FDA
• Recommended dose is 600 mg orally once daily on an empty stomach (no food intake at least 2 hours before or 2 hours after taking)

Press Release: https://investors.nuvationbio.com/news/news-details/2025/U-S--Food-and-Drug-Administration-Approves-Nuvation-Bios-IBTROZI-taletrectinib-a-Next-Generation-Oral-Treatment-for-Advanced-ROS1-Positive-Non-Small-Cell-Lung-Cancer/default.aspx

Andembry® (garadacimab-gxii) subcutaneous injection

Approval Date: 06/16/2025

Indication: Prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years of age and older

Cost*: TBD

Key Consideration:
• Once monthly self-administered subcutaneous injection
• First and only FDA approved treatment targeting factor XIIa for prophylactic use for prevention of HAE attacks

Press Release: https://newsroom.csl.com/2025-06-16-U-S-Food-and-Drug-Administration-Approves-CSLs-ANDEMBRY-R-garadacimab-gxii-,-the-Only-Prophylactic-Hereditary-Angioedema-HAE-Treatment-Targeting-Factor-XIIa-with-Once-Monthly-Dosing-for-All-Patients-From-the-Start

Notable Expanded Indications

Nubeqa® (darolutamide) – expanded to treat metastatic castration-sensitive prostate cancer (mCSPC)

Mavyret® (glecaprevir/pibrentasvir) – expanded to treat acute or chronic hepatitis C virus (HCV) infection in patients at least 3 years of age, with or without compensated cirrhosis (Child-Pugh A)

Talzenna® (talazoparib) – expanded to treat metastatic castration-resistant prostate cancer mCRPC) in combination with Xtandi® (enzalutamide)

Dupixent® (dupilumab) – expanded to treat bullous pemphigoid in adults

Generic Launches

• Tasigna® (nilotinib) capsule
• Fycompa® (perampanel) tablet

Contact Us if you'd like to learn more about Capital Rx's full-service pharmacy benefit management (PBM) solutions and clinical programs.

--------

* Cost: actual patient out-of-pocket costs may be lower, as the list price does not reflect insurance coverage, co-pay support for eligible patients, or financial assistance from patient support

DOWNLOAD NOWBack to Insights

Sign up for our newsletter!

Get the latest information on Judi news, webinars, and industry insights through our newsletter. Sign up now!